Updated Jul 16, 2026
Mokari Atabak has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $6.05M.

Atabak Mokari is the Chief Financial Officer of Corcept Therapeutics Inc, a company focused on developing medications that modulate cortisol for various serious disorders. He has been involved in multiple SEC filings related to his role at the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-17 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 2 | $82.45 | $165 |
| 2026-06-17 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 19.5K | $81.81 | $1.59M |
| 2026-06-17 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 11.1K | $80.94 | $897K |
| 2026-06-17 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 9.4K | $80.02 | $755K |
| 2026-06-17 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise | 40.0K | $19.26 | $770K |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 395 | $70.44 | $28K |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 634 | $0.00 | |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 634 | $70.44 | $45K |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 40.0K | $70.00 | $2.80M |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise | 40.0K | $19.26 | $770K |
| 2026-03-05 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 96 | $35.97 | $3K |
| 2026-03-05 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 397 | $0.00 | |
| 2026-03-05 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 397 | $35.97 | $14K |
| 2025-12-04 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 118 | $79.78 | $9K |
| 2025-12-04 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 178 | $0.00 | |
| 2025-12-04 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 178 | $79.78 | $14K |
| 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 144 | $71.38 | $10K |
| 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 200 | $0.00 | |
| 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 200 | $71.38 | $14K |
| 2025-06-02 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 519 | $71.68 | $37K |
Atabak Mokari is the Chief Financial Officer of Corcept Therapeutics Inc, a company focused on developing medications that modulate cortisol for various serious disorders. He has been involved in multiple SEC filings related to his role at the company.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($6.05M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Mokari Atabak profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.